What's in Denali Therapeutics Inc.'s pipeline?

Denali Therapeutics Inc. has 10 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 8 in Phase 1.

Which companies overlap with Denali Therapeutics Inc.'s portfolio?

Top competitors by shared drug class: Biogen.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/denali-therapeutics-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Denali Therapeutics Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Denali Therapeutics Inc. pipeline: 1 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 1 Phase 2 8 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
AVLAYAH	TIVIDENOFUSP ALFA-EKNM	marketed			Other

Therapeutic area mix

Neurology · 1
Other · 1

Recent regulatory actions (last 90 days)

2026-03-24 — AVLAYAH · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Biogen · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Denali Therapeutics Inc.:

Cite this brief

Drug Landscape (2026). Denali Therapeutics Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/denali-therapeutics-inc. Accessed 2026-05-17.